Proteomics profiling of CD4 + T-cell-derived exosomes from patients with rheumatoid arthritis

Lixin Huang,Ling Liang,Zhuyi Ji,Shuyang Chen,Meng Liu,Qidang Huang,Zhixiang Huang,Shanmiao Sun,Jiali Ding,Jiajun Chen,Xuechan Huang,Shaoling Zheng,Weiming Deng,Yukai Huang,Tianwang Li
DOI: https://doi.org/10.1016/j.intimp.2023.110560
IF: 5.714
2023-07-09
International Immunopharmacology
Abstract:Objectives Our study profiled the CD4 + T-cell-derived exosomes from patients with rheumatoid arthritis (RA) using proteomics. Methods Proteomic analysis of CD4 + T-cell-derived exosomes was performed by tandem mass tags (TMT) combined with LC-MS/MS. We validated the most significantly upregulated and downregulated proteins using ELISA and WB. Results The proteomic results showed that there were 3 upregulated differentially expressed proteins and 31 downregulated differentially expressed proteins in the RA group. The results indicated that dihydropyrimidinase-related protein 3 (DPYSL3) was significantly upregulated in CD4 + T-cell-derived exosomes, whereas proteasome activator complex subunit 1 (PSME1) was significantly downregulated in the RA group. Bioinformatics analysis showed that proteins were enriched in "positive regulation of gene expression", "antigen processing and presentation", "acute-phase response" and "PI3K-AKT signaling" pathways. ELISA verified that compared to the control group, the RA group showed significant upregulation of DPYSL3, and downregulation of PSME1 in CD4 + T-cell-derived exosomes. Conclusions The proteomic analysis results of CD4 + T-cell-derived exosomes from patients with RA suggest that these differentially expressed proteins may be involved in RA pathogenesis. DPYSL3 and PSME1 may become useful biomarkers for RA.
pharmacology & pharmacy,immunology
What problem does this paper attempt to address?